Many of us have forgotten a name, a word, or where we left the keys. Most of the time it is nothing to worry about. For a small group, those small moments slowly turn into something bigger.
A study in JAMA, published in July 2026, found that one blood protein can flag who is most likely to develop cognitive problems in the years ahead. The marker is called phosphorylated tau 217, or p-tau217.
In cognitively healthy older adults with the highest levels of the protein, the five-year risk of progressing to mild cognitive impairment or dementia was 38 percent.
That is not a diagnosis. It is a probability, and most people in the study did not progress.
Also read: How long should you be able to hold a plank? Times sorted by age and sex
The researchers at Mass General Brigham Neuroscience Institute pulled together six long-running cohorts in North America, Japan, and Australia. They followed 2,684 older adults with no cognitive impairment at the start, and 478 of them developed cognitive problems over the years.
What the test actually measures
p-tau217 is a form of the tau protein found in the brain. When Alzheimer's begins to develop, more of it ends up in the blood.
The level in blood roughly tracks the buildup of two kinds of damage in the brain, amyloid plaques and tau tangles. Those changes can begin a decade or more before anyone forgets a name.
The appeal is practical. Until now, confirming the biological changes behind Alzheimer's usually meant a PET brain scan or a spinal tap.
Also read: 8 warning signs of colon cancer that can be mistaken for irritable bowel syndrome
The FDA cleared the first blood test for Alzheimer's last year for people already showing symptoms, and plasma p-tau217 is central to that generation of tests.
Why the 38 percent figure matters
The number applies only to adults with the very highest p-tau217 levels, more than 2.5 standard deviations above the average.
For a middle group with moderately elevated levels, the five-year risk was 24 percent. Over 10 years the risks climbed higher in the top group, though the researchers caution that the longer-range estimates rest on less data.
Everyone else in the study faced far lower odds. The point of the test is not to deliver bad news. It is to spot who might benefit most from early monitoring and from future treatments.
Also read: How drinking kefir every day may change your gut health, immunity and blood pressure
What this means for a routine check-up
Not much, yet. The researchers are clear that a blood-based risk test is not something to ask for at a check-up right now. Professional guidelines still do not recommend screening people without symptoms.
In a statement about the study, senior author Reisa Sperling said there are no treatments yet that can change the course of Alzheimer's for people who find out they are at high risk.
Sperling pointed instead to habits already shown to support brain health as we age.
Regular exercise, a healthy diet, and good sleep remain the most consistent ways to protect how we think and remember.
Also read: One nasal puff may ease treatment-resistant depression for up to eight weeks
Also read: You may be low on this B vitamin and blame it on stress
This article is made and published by Mie Hermansen, who may have used AI in the preparation.